Warning: Creating default object from empty value in /var/www/wp-content/themes/ronneby/redux_framework/ReduxCore/inc/class.redux_filesystem.php on line 29
Evolution Bioscience | News & Analysis
Notice: Function WP_Scripts::localize was called incorrectly. The $l10n parameter must be an array. To pass arbitrary data to scripts, use the wp_add_inline_script() function instead. Please see Debugging in WordPress for more information. (This message was added in version 5.7.0.) in /var/www/wp-includes/functions.php on line 5905
';

Categories

  • Evolution Infographics
  • News & Analysis
+44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search
logo

Notice: Trying to access array offset on value of type bool in /var/www/wp-content/themes/ronneby/inc/aq_resizer.php on line 101

Notice: Trying to access array offset on value of type bool in /var/www/wp-content/themes/ronneby/inc/aq_resizer.php on line 102
Evolution Bioscience
logo
  • Home
  • Clients & Core Services
  • News & Analysis
    • The Future of BioManufacturing
  • IPO Tracker

News & Analysis

Evolution Bioscience specialise in deep market analysis across the full range of biotechnology sectors. Our elite team of consultants augment our extensive commercial and scientific experience with ongoing literature analysis and real-time industry monitoring. Our News & Analysis section features market intelligence reports, data visualisations and unique biotech insights.

AS FEATURED IN

Evolution Bioscience in Genetic Engineering & Biotechnology News
Evolution Bioscience in Forbes
Evolution Bioscience in New Scientist
Evolution Bioscience in Pharmaceutical Manufacturing Magazine
Evolution Infographics
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
More
Share
Evolution Infographics
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
More
Share
Evolution Infographics
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
More
Share
Evolution Infographics
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
More
Share
News & Analysis
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
More
Share
Evolution Infographics
Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015
Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015
More
Share
Evolution Infographics
Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
More
Share
Evolution Infographics
All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation
All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation
More
Share
Evolution Infographics
Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results
Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results
More
Share
News & Analysis
More Efficient and Affordable Large-Scale Biomanufacturing: Have Novo Nordisk Foundation Made a Major Breakthrough?
More Efficient and Affordable Large-Scale Biomanufacturing: Have Novo Nordisk Foundation Made a Major Breakthrough?
More
Share
Evolution Infographics
Global Drug Development IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017
Global Drug Development IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017
More
Share
Evolution Infographics
Manufacturing Gene Therapies: An Impending Crisis or Temporary Growing Pains?
Manufacturing Gene Therapies: An Impending Crisis or Temporary Growing Pains?
More
Share
Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8

RECENT POSTS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

DATA VISUALISATIONS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

About Us

Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

Recent Posts

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
2016 © Evolution Bioscience / Darwin Hutton Partners

Notice: Trying to access array offset on value of type bool in /var/www/wp-content/themes/ronneby/inc/aq_resizer.php on line 101

Notice: Trying to access array offset on value of type bool in /var/www/wp-content/themes/ronneby/inc/aq_resizer.php on line 102
Evolution Bioscience